REGENXBIO Inc. (RGNX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. REGENXBIO Inc. is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform. Key product candidates include sura-vec (wet AMD/DR) in collaboration with AbbVie, RGX-202 (Duchenne muscular dystrophy), and RGX-121 (MPS II) and RGX-111 (MPS I) in collaboration with Nippon Shinyaku.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenues | $108,019 | $21,359 | $114,412 | $110,371 |
| Net Income (Loss) | $22,709 | $(70,871) | $(67,342) | $(64,788) |
| Operating Income (Loss) | $29,263 | $(63,278) | $(54,099) | $(51,151) |
| R&D Expenses | $56,086 | $59,500 | $113,425 | $112,587 |
| Cash & Marketable Securities | $105,517 | $240,900 | $105,517 | $240,900 |
| Accumulated Deficit | $(1,193,369) | $(996,937) | $(1,193,369) | $(996,937) |
Note: Cash and marketable securities figures represent the balance as of June 30, 2026 ($36.5M cash + $69.0M marketable securities) and December 31, 2025 ($34.5M cash + $206.4M marketable securities).
Material Changes vs. Prior Period
- Revenue Surge: Q2 2026 revenue increased 406% year-over-year, driven primarily by a $100 million development milestone from AbbVie for dosing the first patient in the NAAVIGATE trial for sura-vec.
- Profitability: The company reported a net income of $22.7 million in Q2 2026, a significant turnaround from a net loss of $70.9 million in Q2 2025, largely due to the milestone revenue.
- Royalty Decline: Royalties from Novartis (Zolgensma and Itvisma) decreased significantly ($14.6M drop in Q2) due to the expiration of licensed patents for Zolgensma in the U.S. in January 2026, despite stable sales volumes.
- Liquidity Position: Marketable securities decreased from $206.4 million at year-end 2025 to $69.0 million at June 30, 2026, as the company utilized investments to fund operations.
- Debt Obligations: Royalty monetization liabilities totaled $181.5 million, consisting of the 2020 Royalty Purchase Agreement ($11.8M) and the 2025 Royalty Bond ($169.7M).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash, cash equivalents, and marketable securities as of June 30, 2026 ($105.5M), combined with the $100M AbbVie milestone received in July 2026 and $107.8M in net proceeds from a July 2026 public offering, are sufficient to fund operations into the fourth quarter of 2027.
- RGX-202 (Duchenne): Positive topline results from the pivotal Phase III trial were announced in May 2026. The company plans to submit a Biologics License Application (BLA) under the accelerated approval pathway in Q3 2026, targeting potential FDA approval in H2 2027.
- RGX-121 (MPS II): Following a Complete Response Letter (CRL) in February 2026, the company aligned with the FDA in June 2026. No additional studies are required; the company plans to resubmit the BLA in Q3 2026.
- RGX-111 (MPS I): Development remains on a partial clinical hold following the identification of a tumor in a patient. The company is working with the FDA to resolve the hold.
- Legal Risks: The company is facing a putative securities class action lawsuit regarding statements made about RGX-111 and RGX-121. Management believes it has meritorious defenses and has not recorded a liability.
Investor Verification Checklist
- AbbVie Milestone Collection: Verify the receipt of the $100 million milestone payment from AbbVie, which was recorded as receivable at period end but collected in July 2026.
- July 2026 Offering Proceeds: Confirm the net proceeds of approximately $107.8 million from the public offering of common stock and pre-funded warrants completed in July 2026.
- RGX-121 BLA Resubmission: Monitor the timeline and FDA response to the planned Q3 2026 BLA resubmission for RGX-121.
- RGX-111 Clinical Hold: Track updates on the resolution of the partial clinical hold for RGX-111 and any impact on the Nippon Shinyaku collaboration.
- Royalty Monetization Servicing: Assess the sufficiency of future royalty streams (Zolgensma/Itvisma and Nippon Shinyaku milestones) to service the $181.5 million in royalty monetization liabilities.